Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin☆
Section snippets
Patients and methods
This study was designed as an ancillary trial to the TAP Investigation, a randomized, double-masked phase III clinical trial that was performed in 22 tertiary referral centers in the United States and Europe.1, 2 The ICGA analysis was carried out as a prospective, single-center ancillary study. The protocol for this ancillary study complied with the Declaration of Helsinki and with the recommendations of the governing institutions and received the approval of the TAP Study Advisory Group.
Results
A total of 60 patients participated in the TAP trial at the Luebeck study center. All consecutive TAP participants underwent standardized ICGA at each presentation according to protocol and were included in the analysis. Double masking was maintained during the treatment procedure, the ICGA examinations, and the entire data analysis. Retrospective unmasking identified a group of 40 eyes assigned to verteporfin treatment, and a control group of 20 eyes assigned to sham treatment. Follow-up was
Discussion
Photodynamic therapy is an intervention specifically addressing a selective manipulation of vascular structures and provides an excellent rationale for the treatment of ocular neovascular disease. In the treatment of CNV lesions, obvious vascular effects, including vascular obliteration and resolution of leakage, are seen clinically and by FA. Indocyanine green angiography is a diagnostic method with a high sensitivity for the imaging of subretinal vascular layers such as the neovascular
References (18)
- et al.
Indocyanine green angiography and occult choroidal neovascularization
Ophthalmology
(1994) - et al.
Evaluating persistent and recurrent choroidal neovascularization. The role of indocyanine green angiography
Ophthalmology
(1998) - et al.
Identification of ingrowth site of idiopathic subfoveal choroidal neovascularization by indocyanine green angiography
Ophthalmology
(2000) - et al.
Evolution of age-related macular degeneration with choroidal perfusion abnormality
Am J Ophthalmol
(1992) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials—TAP report 2
Arch Ophthalmol
(2001)Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials—TAP report 1
Arch Ophthalmol
(1999)- et al.
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of a single treatment in a phase 1 and 2 study
Arch Ophthalmol
(1999) - Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal...
Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study
Arch Ophthalmol
(1991)
Cited by (61)
Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials
2021, Progress in Retinal and Eye ResearchCitation Excerpt :Moreover, structure function correlation using an artificial intelligence algorithm (von der Emde et al., 2019a), as well as conventional structure function correlation (Sulzbacher et al., 2012), demonstrated concurrent validity. Ability to detect change in terms of mesopic sensitivity was established in longitudinal studies examining the effect of photodynamic therapy (Schmidt-Erfurth and Michels, 2003), and anti-VEGF therapy (Bolz et al., 2010; Prager et al., 2008; Squirrell et al., 2010). Greater degrees of dark-adapted versus mesopic sensitivity losses were reported for patients with CNV secondary to AMD (von der Emde et al., 2019b).
Impact of vitreomacular adhesion on ranibizumab mono- and combination therapy for neovascular age-related macular degeneration
2014, American Journal of OphthalmologyCitation Excerpt :Combination therapy with verteporfin in patients with posterior vitreous detachment, on the other hand, resulted in a reduction of potential vision gain already in the earliest phase of the study. This relative loss of vision is potentially attributable to the vaso-occlusive effect of PDT on the exposed choriocapillaris and subsequent damage to the neurosensory retina, particularly when using standard- (full-) fluence PDT.36 Nevertheless, verteporfin treatment effectively suppresses CNV growth and leakage, as shown by the rapid and sustained effect on central retinal thickness in the PDT arm.
Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: Changes of aqueous vascular endothelial growth factor
2013, American Journal of OphthalmologyAssociation between Foveal Photoreceptor Integrity and Visual Outcome in Neovascular Age-related Macular Degeneration
2009, American Journal of OphthalmologyCitation Excerpt :The post-PDT hypofluorescence within the treated area often was observed with ICGA. However, it is still controversial if this phenomenon affects VA.40–42 Optical coherence tomography has been used to evaluate retinal edema, serous RD, and pigment epithelium detachment in AMD.4,5,12,13
The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration
2008, Progress in Retinal and Eye Research
- ☆
Manuscript no. 220347
The Massachusetts General Hospital, Harvard Medical School, is an owner of the patent covering the use of verteporfin to treat ocular neovascular disease. U. Schmidt-Erfurth is an inventor on the patent. Massachusetts General Hospital’s institutional patent policy and procedures include royalty-sharing provisions for inventors.
The authors have no proprietary interest in the Heidelberg Retina Angiograph.